arrow
T

Tomasz Olesiński

m. sklodowska-curie national research institute of oncology
H指数:13
被引数:1,955

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

De-escalated total neoadjuvant therapy for the non-operative management of rectal cancer: Results of the NOM-3/TNT prospective cohort study

降强度的总新辅助疗法用于直肠癌症的非手术管理:NOM-3/TNT前瞻性队列研究的结果

2026-08-200
OAAI
To push or to pull? A clinical audit on the efficacy and safety of the pull and push percutaneous endoscopic gastrostomy techniques in oncological patients

推还是拉?对肿瘤患者经皮内镜下胃造口术的疗效和安全性的临床审核

2023-11-103
OAAI
The molecular network of the proteasome machinery inhibition response is orchestrated by HSP70, revealing vulnerabilities in cancer cells
2022-09-0112
OA
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial

Pembrolizumab与紫杉醇治疗先前治疗的PD-L1-positive晚期胃癌或胃食管交界癌: 随机3期KEYNOTE-061试验的2年更新

2021-09-01100
OAAI
Watch-and-wait strategy in rectal cancer: Is there a tumour size limit? Results from two pooled prospective studies
2021-07-0123
PREAI
The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice

常规治疗高危分子分型胃肠道间质瘤 (GIST) 患者3年伊马替尼辅助治疗分析

EJSO
IF2.9
2021-05-018
PREAI
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
LANCET
IF88.5
2018-07-011.0K
PREAI